Group items tagged

MaRS originally stood for Medical and Research Sciences, but has since shied away from that label, said Ross Wallace, director of corporate strategy. The organization doesn't want to be pigeonholed as being just a life sciences or biotechnology outfit -- it lends equal weight to information communications and advanced manufacturing. MaRS may be Toronto-based, but its mandate is province-wide, said Wallace. By joining forces with organizations in other parts of Ontario, MaRS is more likely to fulfill that mandate, he said.

The three organizations aim to share best practices and contacts, and lean on the strengths of their respective regions. All three may have good venture capital resources, for example, but specialties that may be peculiar to a certain area.

Dale added that the MaRs Network is open to working with other Canadian technology organizations, including those with a national or a regional focus.

"There's an enthusiasm in the research community that's very exciting to be part of," says Dr. Keller, who now heads the McEwan Centre for Regenerative Medicine.

Dr. Hudson, who left Quebec to head the Ontario Institute for Cancer Research, says the city's "tremendous power" is built on a strong history: Stem-cell research began here. "It's innovative," he says of Toronto. "I've never felt closer in my research career to thinking we will have an impact. I feel my goals are going to happen here."

Still, John Evans, board chairman of the non-profit MaRS Centre, which helps to turn research into viable businesses, envisages a day when research is seen as a social and economic driver, and the city shines as brightly as better-known centres such as Boston and Palo Alto.

This is one of many new commercilization ventures that will be initiated by MaRS Innovation, our partner in commercialization of research with 13 other academic institutions across the Greater Toronto Area,” said Paul Young, U of T’s Vice-President, Research. “We at U of T are delighted that this innovation from Dr. Lee will be taken to the marketplace to the benefit of society and the economy of Ontario and Canada.” 

With the launch of this second commercial opportunity, MaRS Innovation will continue to aggregate the exceptional science of its institutional members by being a one-stop commercialization centre for industry, entrepreneurs and investors. MaRS Innovation is expediting the transformation of the Toronto-based research into a powerful commercialization engine. 

“MaRS Innovation is deeply committed to facilitating strategic research collaborations with industry partners, strengthening the innovation capacity of Canadian industry through adoption of new technologies, and launching a new generation of robust, high-growth Canadian companies that will become global market leaders,” added Dr. Hofstein. “We look forward to working closely with all of our institutional members and to continue to jointly announce exciting commercial opportunities.”

MaRS Innovation is dedicated to bringing brilliant discoveries to market by converting the outstanding science of its member institutions into outstanding economic results for Canada and the world.

"MaRS Innovation is a unique global initiative, and I must commend the institutional leaders in Toronto for pulling this innovation powerhouse together to strengthen commercialization output. In my experience, good science is the single most important ingredient for success in this business. Toronto is already known as one of the strongest science cities in the world, and it continues to grow. Leading MaRS Innovation is a wonderful opportunity to do something remarkable."

Dr. Tim McTiernan, assistant vice-president (research) and executive director of The Innovations Group (TIG), U of T's research commercialization operation, said Mars Innovation will provide significant benefits to U of T.

And he said that MI's role as a resource "is like putting a turbo charger on an engine. Having MI working with us and the other member organizations is a huge step in taking advantage of the enormous potential in the Toronto research community. Commercialization offices acting independently will not be able to manage in nearly as effective a manner as will be possible with the expertise of MaRS Innovation."

W. Geoffrey Beattie – Deputy Chairman & President, Woodbridge Company Limited, Thomson Reuters Corporation, Toronto Christopher C. Capelli – Vice President, Technology Based Ventures, Office of Technology Commercialization, University of Texas, M.D. Anderson Cancer Center, Houston, TX Ron Close – Information technology entrepreneur, Entrepreneur-in-Residence, MaRS, and Executive Entrepreneur-in-Residence, The Richard Ivey School of Business, The University of Western Ontario, London, ON Nicholas Darby – Formerly Director of Physical Sciences, Corporate Venture Capital, Dow Chemical Company, President, Darby & Associates Consulting LLC, Midland, MI  Mary Jo Haddad – President & CEO, The Hospital for Sick Children, Toronto Jacqueline H.R. Le Saux – Former General Counsel, North America and Corporate Secretary, Patheon, Inc., Toronto David A. Leslie - Chair, Sunnybrook Health Sciences Centre, and Former Chairman & CEO, Ernst & Young, Toronto Michael H. May – President & CEO, Rimon Therapeutics, Toronto Chandra J. Panchal – Founder, President & CEO, Axcelon Biopolymers Corp., Dollard-des-Ormeaux, QC Ilse Treurnicht – CEO, MaRS Discovery District, Toronto Donald A. Wright – President & CEO, The Winnington Capital Group Inc., Toronto

MaRS Innovation serves as a business accelerator platform with a single point of entry for industry partners and investors.  It will increase the scale, scope and viability of IP offerings, and the quantity and quality of deal flow from partner institutions.  MaRS Innovation will also facilitate strategic research collaborations with industry partners, strengthen the innovation capacity of Canadian industry through adoption of new technologies from its member institutions, and launch a new generation of robust, high-growth Canadian companies that will become global market leaders.   The quality of the combined discovery pipeline will catalyze and attract sources of risk capital for translational research, market validation, company formation and growth.  “MaRS Innovation represents a unique and timely platform to contribute in a meaningful way to Canada’s knowledge economy, leveraging Toronto’s remarkable research excellence.  The vision and serious commitment of its members to work together to transform our commercialization results, and the support of the Federal Government, made this possible.  The announcement of this outstanding group of leaders to the Board of Directors for MaRS Innovation is an exciting step forward,” said Ilse Treurnicht, MaRS CEO and interim Managing Director of MaRS Innovation.

Tonight, in Toronto, Pawson will be honoured for his latest achievement: Winning the prestigious Kyoto Prize in Basic Sciences. He will share the podium with Charles Taylor, professor emeritus at McGill University, who won the prize in the Arts and Philosophy category. They are the first Canadians to win the coveted prize from the Inamori Foundation of Kyoto.

Pawson was recognized for his research into the way cells communicate with each other, which has made possible the development of drugs that halt the multiplication of certain types of cancer cells, among other breakthroughs. His lab has helped lay the groundwork for this new generation of drugs.